Development and characterization of palbociclib-loaded PLGA nanobubbles for targeted cancer therapy

The objective of this study was to develop and optimize palbociclib-loaded nanobubbles for targeted breast cancer therapy. Biocompatible poly(DL-lactide-co-glycolide) was used to create nanobubbles loaded with palbociclib. The formulation process was meticulously crafted using a three-level Box-Behn...

Full description

Saved in:
Bibliographic Details
Published inAnnales pharmaceutiques françaises
Main Authors Kumar, Boddu Kishore, Kumar, Gubbiyappa Shiva
Format Journal Article
LanguageEnglish
Published France 11.09.2024
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The objective of this study was to develop and optimize palbociclib-loaded nanobubbles for targeted breast cancer therapy. Biocompatible poly(DL-lactide-co-glycolide) was used to create nanobubbles loaded with palbociclib. The formulation process was meticulously crafted using a three-level Box-Behnken design and a double emulsion solvent evaporation method to precisely tailor the nanobubbles' properties. The Derringer's desirability method optimized variables by transforming responses into a desirability scale, resulting in a global desirability value. Optimal settings, A: 526.97mg, B: 250mg,C: 2.0% w/v, D: 6101rpm, achieved a D value of 0.949. Palbociclib nanobubbles demonstrated a smaller particle size (31.78±2.12) than plain nanobubbles (38.56±3.56). PDI values indicated a uniform size distribution. The zeta potential remained consistent, with values of -31.34±3.36 for plain and -31.56±3.12 for drug-loaded nanobubbles. Encapsulation efficiency was 70.12%, highlighting effective drug encapsulation. Palbociclib release was significantly higher from nanobubbles in pH 7.4, especially with ultrasound, releasing almost 99.34% of the drug. Hemolytic activity assays confirmed safety for injection. Fluorescent intensity analysis revealed a two-fold increase in cellular uptake of palbociclib facilitated by ultrasound. The MTT assay demonstrated enhanced cytotoxicity of palbociclib-loaded nanobubbles, especially with ultrasound, emphasizing their potential for improved therapeutic efficacy. The IC values for palbociclib, without ultrasound, and with ultrasound were 98.3μM, 72.34μM, and 61.34μM, respectively. The significant findings of this study emphasize the potential of palbociclib-loaded nanobubbles as a promising therapeutic system for improved breast cancer treatment.
AbstractList The objective of this study was to develop and optimize palbociclib-loaded nanobubbles for targeted breast cancer therapy. Biocompatible poly(DL-lactide-co-glycolide) was used to create nanobubbles loaded with palbociclib. The formulation process was meticulously crafted using a three-level Box-Behnken design and a double emulsion solvent evaporation method to precisely tailor the nanobubbles' properties. The Derringer's desirability method optimized variables by transforming responses into a desirability scale, resulting in a global desirability value. Optimal settings, A: 526.97mg, B: 250mg,C: 2.0% w/v, D: 6101rpm, achieved a D value of 0.949. Palbociclib nanobubbles demonstrated a smaller particle size (31.78±2.12) than plain nanobubbles (38.56±3.56). PDI values indicated a uniform size distribution. The zeta potential remained consistent, with values of -31.34±3.36 for plain and -31.56±3.12 for drug-loaded nanobubbles. Encapsulation efficiency was 70.12%, highlighting effective drug encapsulation. Palbociclib release was significantly higher from nanobubbles in pH 7.4, especially with ultrasound, releasing almost 99.34% of the drug. Hemolytic activity assays confirmed safety for injection. Fluorescent intensity analysis revealed a two-fold increase in cellular uptake of palbociclib facilitated by ultrasound. The MTT assay demonstrated enhanced cytotoxicity of palbociclib-loaded nanobubbles, especially with ultrasound, emphasizing their potential for improved therapeutic efficacy. The IC values for palbociclib, without ultrasound, and with ultrasound were 98.3μM, 72.34μM, and 61.34μM, respectively. The significant findings of this study emphasize the potential of palbociclib-loaded nanobubbles as a promising therapeutic system for improved breast cancer treatment.
Author Kumar, Boddu Kishore
Kumar, Gubbiyappa Shiva
Author_xml – sequence: 1
  givenname: Boddu Kishore
  surname: Kumar
  fullname: Kumar, Boddu Kishore
  organization: GITAM School of Pharmacy, GITAM Deemed to be University, 502329 Hyderabad, Telangana, India
– sequence: 2
  givenname: Gubbiyappa Shiva
  surname: Kumar
  fullname: Kumar, Gubbiyappa Shiva
  email: shivakumar.gubbiyappa@gitam.edu
  organization: GITAM School of Pharmacy, GITAM Deemed to be University, 502329 Hyderabad, Telangana, India. Electronic address: shivakumar.gubbiyappa@gitam.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39270837$$D View this record in MEDLINE/PubMed
BookMark eNo1j11LwzAUhnMxcR_6D0TyB1pP0iZpLsfUKQz0YvfjJD11HW1S2k6Yv96C8-rl4YUHniWbhRiIsQcBqQChn05pd8S-xVSCzFOwKYCasQUAZEmuwM7ZchhOE2ktxC2bZ1YaKDKzYP6ZvqmJXUth5BhK7icR-pH6-gfHOgYeK95h46KvfVO7pIlYUsk_d9s1DxiiOzvX0MCr2PMR-y8ap9dj8DTxkXrsLnfspsJmoPvrrtj-9WW_eUt2H9v3zXqXeKG0SSr0kkRuwFBmtUdhS-Eqq0EWBWRUqCKnzNlSKSyFhcIorb0UVSGFqIyUK_b4p-3OrqXy0PV1i_3l8B8rfwEhb1jY
ContentType Journal Article
Copyright Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
DBID NPM
DOI 10.1016/j.pharma.2024.09.005
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 39270837
Genre Journal Article
GroupedDBID 08J
08T
0R~
457
5GY
AAEDT
AALRI
AAXUO
AFNOS
AFTJW
ALMA_UNASSIGNED_HOLDINGS
AOOFG
EBS
F5P
FDB
NPM
O9-
P2P
SEM
SES
ID FETCH-LOGICAL-c1567-fac2e14707e396ca19d1bf96028803e8584e3b9d55ad19087566c21f8211f722
ISSN 0003-4509
IngestDate Sat Nov 02 12:31:57 EDT 2024
IsPeerReviewed true
IsScholarly true
Keywords Encapsulation efficiency
Targeted drug delivery
Administration ciblée de medicaments
Palbociclib
Cytotoxicity
Cytotoxicité
Efficacité d’encapsulation
Libération déclenchée par ultrasons
Ultrasound-triggered release
Nanobulles PLGA
PLGA nanobubbles
Language English
License Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1567-fac2e14707e396ca19d1bf96028803e8584e3b9d55ad19087566c21f8211f722
PMID 39270837
ParticipantIDs pubmed_primary_39270837
PublicationCentury 2000
PublicationDate 2024-Sep-11
PublicationDateYYYYMMDD 2024-09-11
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-Sep-11
  day: 11
PublicationDecade 2020
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Annales pharmaceutiques françaises
PublicationTitleAlternate Ann Pharm Fr
PublicationYear 2024
SSID ssj0036611
Score 2.3593562
Snippet The objective of this study was to develop and optimize palbociclib-loaded nanobubbles for targeted breast cancer therapy. Biocompatible...
SourceID pubmed
SourceType Index Database
Title Development and characterization of palbociclib-loaded PLGA nanobubbles for targeted cancer therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/39270837
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBftCqMvo_ve2g09jL6kDpGsWM5jV7aWtSuBZtC3cvowychsQ9JB-tfvJPmLZKNdX0zwBSH8-_n0O-nuTMinzLJYg6tYTuQgEjYeRSDUIAJmNE8sxAJcvfP3y-Tsh_h2PbxuGyr46pKl6uu7v9aVPAZVvIe4uirZ_0C2GRRv4G_EF6-IMF4fhHEn4yfUpzXdl-8aJVjCXCEAGuPiaF6AQYE5vjg97uWQF-pWqbldhFRDnxKOVu144FMPm3YD3WbL-Pdy2uyDu1Wll-F65w_cpTuH6pwOVdnbnwtjbnvns8W0aFNtG-spTmK2grKE3tV09hu6-xBcuKSJyk_WvjWOxNA3O9h0zGGP4Gc_zLDvBvD9ZX3N9bKDVfnLg4WyTaI6lPdb19pl16Ztsi1T5_gu3fZNWJpjFCPNJxTdVOtaSp_wtzm1XfK0Hm4t6vDqY7JHnlVhAz0OHHhOtmz-ghyOAxCrIzppy-gWR_SQjtuO5KuXRHeIQpEodJ0otMjoJlGoIwrtEIUiUWhNFBqIQiuivCKTr18mJ2dR9XWNSGPMLqMMNLdMyIHEFzTRwEaGqQwDWo4uPbYpKlMbq5EZDsGgasS4Nkk0Z1nKGcsk56_Jk7zI7VtCUy0MGACU4lJYPgJmE20GqWZMYzSv3pE34dndlKGDyk39VN__07JPdluSHZCdDF9Z-wH131J99Jj-ASTtXAw
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+characterization+of+palbociclib-loaded+PLGA+nanobubbles+for+targeted+cancer+therapy&rft.jtitle=Annales+pharmaceutiques+fran%C3%A7aises&rft.au=Kumar%2C+Boddu+Kishore&rft.au=Kumar%2C+Gubbiyappa+Shiva&rft.date=2024-09-11&rft.issn=0003-4509&rft_id=info:doi/10.1016%2Fj.pharma.2024.09.005&rft_id=info%3Apmid%2F39270837&rft_id=info%3Apmid%2F39270837&rft.externalDocID=39270837
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4509&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4509&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4509&client=summon